Track topics on Twitter Track topics that are important to you
HeartSciences is leading innovation in the field of electrocardiography through the application of continuous wavelet transform (CWT) signal processing and artificial intelligence. Wavelet signal processing is currently used in many different industries as an important tool to provide insights and new valuable data related to spectral analysis of a signal. HeartSciences’ MyoVista® Wavelet ECG (wavECG™) is a first-to-market 12-lead resting electrocardiograph with new informatics based on wavelet signal processing. Patented informatics focus on energy related information rather than conventional voltage-based information. HeartSciences mission is to enable accurate, affordable screening for the early detection of heart disease.
In addition to proprietary informatics, the MyoVista wavECG Device has full 12-lead resting ECG capabilities including analysis using the Glasgow Algorithm, one of the world’s most respected interpretive algorithms. The device has a 15.6-inch high-resolution touchscreen display and incorporates many features commonly associated with a tablet device requiring minimal user training with no change in ECG clinical workflow. The MyoVista wavECG Device is not currently FDA approved for commercial sale or distribution in the United States.
HeartSciences is a privately-held U.S. corporation based in Southlake, Texas.
Gene Gephart, +1-737-346-1089
Zimmons International Communications, Inc.
Jennifer K. Zimmons, +1-917-214-3514
A 188-patient study in the Journal of the American College of Cardiology showed that use of HeartSciences' MyoVista electroca -More-
SOUTHLAKE, Texas, June 25, 2018 -- (BioPortfolio) — HeartSciences, an innovative medical device company, is proud to announce its participation as an exhibitor at the upcoming 2018 Internat...
Hall 5.1 USA-CEO Center (S26-32/R19-25-5) HeartSciences, an innovative medical device company, is proud to announce its participation as an exhibitor at the upcoming 20...
HeartSciences also participates in the ACC Future Hub at Booth#3517, Space FH7 SOUTHLAKE, Texas, March 8, 2018 --(BUSINESSWIRE)—HeartSciences, an innovative medical device company, announced...
HeartSciences, an innovative medical device company, is proud to announce its participation as an exhibitor at the upcoming 2018 International Congress on Electrocardiology...
Southlake, Texas – May 2, 2018 – HeartSciences, a U.S.-based medical device company that is leading innovation in the field of electrocardiology through the application of continuous ...
HeartSciences is delighted to have been highlighted as “Start-Up to Watch” in the June 8, 2018 issue of the MedTech Strategist. The article titled
Study demonstrates promising new capabilities for MyoVista® ECG device in detecting Abnormal Cardiac Function SOUTHLAKE, Texas, April 10, 2018 - (BioPortfolio) HeartSciences, a medical...
Purpose of this clinical investigation: clinical evaluation/accuracy of HeartSciences MyoVista High-Sensitivity (hsECG) 12 lead Electrocardiogram device, for patients presenting with cardi...
HeartSciences is leading innovation in the field of electrocardiography through the application of continuous wavelet transform (CWT) signal processing and artificial intelligence. Wavelet signal pr...
We have published hundreds of HeartSciences news stories on BioPortfolio along with dozens of HeartSciences Clinical Trials and PubMed Articles about HeartSciences for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of HeartSciences Companies in our database. You can also find out about relevant HeartSciences Drugs and Medications on this site too.